Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Resource Type
Article
Authors
Lartigau, E ; Patton, S ; Thompson, A ; Winkler, M ; Wells, P ; Lymberiou, T ; Saunders, D ; Vilarino-Varela, M ; Vavassis, P ; Tsakiridis, T ; Carlson, R ; Rodrigues, G ; Tanguay, J ; Iqbal, S ; Morgan, S ; Mihai, A ; Li, A ; Din, O ; Panades, M ; Wade, R ; Rimmer, Y ; Oommen, N ; Tree, Alison C ; Ostler, Peter ; van der Voet, Hans ; Chu, William ; Loblaw, Andrew ; Ford, Daniel ; Tolan, Shaun ; Jain, Suneil ; Martin, Alexander ; Staffurth, John ; Armstrong, John ; Camilleri, Philip ; Kancherla, Kiran ; Frew, John ; Chan, Andrew ; Dayes, Ian S ; Duffton, Aileen ; Brand, Douglas H ; Henderson, Daniel ; Morrison, Kirsty ; Brown, Stephanie ; Pugh, Julia ; Burnett, Stephanie ; Mahmud, Muneeb ; Hinder, Victoria ; Naismith, Olivia ; Hall, Emma ; van As, Nicholas
Source
In The Lancet Oncology October 2022 23(10):1308-1320
Subject
Primary Research Articles
Language
ISSN
1470-2045